Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Therapeutics Inks SNP Collaboration with Oxagen

Premium

HAYWARD, Calif.--Lynx Therapeutics announced that it will collaborate with Oxagen of Oxford, UK, to discover and validate disease-associated single-nucleotide polymorphisms (SNPs). The program will initially focus on inflammatory bowel disease, but may be extended to other common disorders. No financial terms were disclosed.

Lynx will apply its proprietary SNP-extracting and genotyping technologies to identify disease-associated SNPs from large, well characterized patient populations available to Oxagen through its clinical collaborators. Oxagen will map and further refine the regions of association defined by these SNPs to locate disease genes and identify functional polymorphisms within them.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.